The reported ($0.36) earnings per share (eps) for the quarter, missing analysts' consensus estimates of ($0.33) by $0.03. — stock price and discussion | stocktwits.
Vyne Therapeutics Inc Vyne Reports Q3 Loss Lags Revenue Estimates Nasdaq
Vyne stock forecast our latest prediction for vyne therapeutics inc's stock price was made on the aug.
Vyne stock forecast zacks. Vyne therapeutics last released its quarterly earnings data on november 10th, 2021. Vyne | complete vyne therapeutics inc. On average, they expect vyne therapeutics' stock price to reach $6.50 in the next year.
Analyst price target for vyne i we calculate consensus analyst ratings for stocks using the most recent rating from each wall street analyst that has rated a stock within the last twelve months. Vyne therapeutics has generated ($1.77) earnings per share over the last year ( ($1.77) diluted earnings per share). And zilxi for the treatment of inflammation lesions of.
On the other hand, the stock currently carries a zacks rank of #3. We feel now is a pretty good time to analyse vyne therapeutics inc.'s (nasdaq:vyne) business as it appears the company may be on the cusp of a considerable accomplishment. 16, 2021 when the stock price was at 1.78$.
Three analysts have made estimates for vyne therapeutics’ earnings, with the lowest sales estimate coming in at $4.00 million and the highest estimate coming in at $4.83 million. This compares to loss of $0.52 per. Nasdaq updated dec 4, 2021 12:36 am.
The company has not been able to beat consensus revenue estimates over the last four quarters. Vyne therapeutics upgraded by zacks investment research on 10/14/2021. Here's what analysts forecast for vyne therapeutics inc.
Seeing company management invest large sums of money in a stock can be just as useful as. (vyne) came out with a quarterly loss of $0.37 per share versus the zacks consensus estimate of a loss of $0.40. This has resulted in an earnings esp of 0%.
Each analyst's rating is normalized to a standardized rating. In a note to investors, the firm issued a new rating of buy. Vyne therapeutics stock has undergone multiple analysts rating changes in the recent past.
The analysts previously had rating of hold. This compares to loss of $0.52 per share a year ago. Their forecasts range from $6.00 to $7.00.
Vyne therapeutics inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. This suggests a possible upside of 441.7% from the stock's current price. Equities analysts expect vyne therapeutics inc.
This compares to loss of $3.80 per share a year ago. In the medium term (3months), vyne's stock price. For vyne therapeutics inc.the most accurate estimate is the same as the zacks consensus estimate, suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate.
(nasdaq:vyne) to announce $4.41 million in sales for the current quarter, zacks investment research reports. (vyne) came out with a quarterly loss of $0.36 per share versus the zacks consensus estimate of a loss of $0.34. (vyne) came out with a quarterly loss of $0.36 per share versus the zacks consensus estimate of a loss of $0.34.
Vyne Therapeutics Inc Vyne May Report Negative Earnings Know The Trend Ahead Of Next Weeks Release Nasdaq
Stock Market Education - Zackscom
Zacks Analysts Expect Freeline Therapeutics Holdings Plc Nasdaqfrln Will Announce Earnings Of -074 Per Share - Opera News
Vyne Therapeutics Inc Vyne Stock Price Quote News Stock Analysis
Flex Stock Forecast 2025
Vyne Vyne Therapeutics Inc - Full Company Report - Zackscom
Zacks Research System
Motley Fool Vs Zacks - Which Is Better Side By Side Comparison 2021
3 Growth Stocks With The Highest Zacks Rank
Us707 - Thats What Analysts Think Vyne Therapeutics Inc Nasdaqvyne Is Worth After These Results
Zacks Analysts Expect Evolus Inc Nasdaqeols Will Announce Quarterly Sales Of 2774 Million - Opera News
Slno - Soleno Therapeutics Inc - Cnnmoneycom
Vyne Stock Forecast Price News Vyne Therapeutics
Vyne Therapeutics Inc Nasdaqvyne Expected To Post Quarterly Sales Of 508 Million - Opera News
Zacks Investment Research Reviews - 97 Reviews Of Zackscom Sitejabber
Zacks Stock Education - Billion Dollar Secret
3 Strong Buy Healthcare Stocks Under 5 With Triple-digit Growth Prospects Nasdaq
Ocgn Price Target Why Ocugen Stock Skyrocketed Today The Motley Fool The Average Ocgn Stock Price Target Is 3233 With A High Estimate Of 800 And A Low Estimate Of 07000 - Daniel Hetherington
Vyne Therapeutics Inc Vyne Stock Price Quote News Stock Analysis